Biopharma · FDA Approvals · Stock

CTOR Citius Oncology

Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exc…

Assets on file: denileukin diftitox-cxdl

Catalyst calendar

Dated catalysts for CTOR, including recently decided ones.

October 2026

Recent first-hand events

Every first-hand event for CTOR, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 4, 2026
09:30 PM
CTORCitius Oncology

Citius Oncology (CTOR) Presents Positive LYMPHIR QoL Data at EORTC-CLTG 2026

Positive quality-of-life (Skindex-29, FACT-G) and pruritus data from the registrational Study 302 of already-approved LYMPHIR were presented at the EORTC-CLTG 2026 meeting; these exploratory results are not in the label.

Conference presentationSEC 8-K1 update

Peers by market cap

Companies in the same sector closest to CTOR in market value.

CTOR FDA Calendar & Catalysts — Citius Oncology | Biopharma · FDA Approvals | SimianX AI